Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-cell genomics study of palbociclib resistance in metastatic breast cancer
NL-OMON52225Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of palbociclib in breast cancer, sponsored by Erasmus MC. Primary endpoint: Chromosomal alterations at progression. Started Feb 2022; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52225.